Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin

Autoři	LAUSEKER Michael BACHL Katharina TURKINA Anna FABER Edgar PREJZNER Witold OLSSON-STROMBERG, Ulla BACCARANI Michele LOMAIA Elza ŽÁČKOVÁ Daniela OSSENKOPPELE Gert GRISKEVICIUS Laimonas SCHUBERT-FRITSCHLE Gabriele SACHA Tomasz HEIBL Sonja KOSKENVESA Perttu BOGDANOVIC Andrija CLARK Richard E. GUILHOT Joelle HOFFMANN Verena S. HASFORD Joerg HOCHHAUS Andreas PFIRRMANN Markus
Rok publikování	2019
Druh	Článek v odborném periodiku
Časopis / Zdroj	American Journal of Hematology
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	http://dx.doi.org/10.1002/ajh.25628
Doi	http://dx.doi.org/10.1002/ajh.25628
Klíčová slova	WORLD-HEALTH-ORGANIZATION; CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE INHIBITORS; 2904 CML PATIENTS; RANDOMIZED CML; SURVIVAL; MANAGEMENT; IMATINIB; ERA; RECOMMENDATIONS
Popis	Chronic myeloid leukemia (CML) is usually diagnosed in chronic phase, yet there is a small percentage of patients that is diagnosed in accelerated phase or blast crisis. Due to this rarity, little is known about the prognosis of these patients. Our aim was to identify prognostic factors for this cohort. We identified 283 patients in the EUTOS population-based and out-study registries that were diagnosed in advanced phase. Nearly all patients were treated with tyrosine kinase inhibitors. Median survival in this heterogeneous cohort was 8.2 years. When comparing patients with more than 30% blasts to those with 20-29% blasts, the hazard ratio (HR) was 1.32 (95%-confidence interval (CI): [0.7-2.6]). Patients with 20-29% blasts had a significantly higher risk than patients with less than 20% blasts (HR: 2.24, 95%-CI: [1.2-4.0], P = .008). We found that the blast count was the most important prognostic factor; however, age, hemoglobin, basophils and other chromosomal aberrations should be considered as well. The ELTS score was able to define two groups (high risk vs non-high risk) with an HR of 3.01 (95%-CI: [1.81-5.00], P < .001). Regarding the contrasting definitions of blast crisis, our data clearly supported the 20% cut-off over the 30% cut-off in this cohort. Based on our results, we conclude that a one-phase rather than a two-phase categorization of de novo advanced phase CML patients is appropriate.